Your browser doesn't support javascript.
loading
Long-Term Outcomes Following Definitive or Adjuvant Proton Radiotherapy for Adenoid Cystic Carcinoma.
Augustin, Etzer; Holtzman, Adam L; Dagan, Roi; Bryant, Curtis M; Indelicato, Daniel J; Morris, Christopher G; Deraniyagala, Rohan L; Fernandes, Rui P; Bunnell, Anthony M; Nedrud, Stacey M; Mendenhall, William M.
Afiliação
  • Augustin E; Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, Florida, USA.
  • Holtzman AL; Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida, USA.
  • Dagan R; Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, Florida, USA.
  • Bryant CM; Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, Florida, USA.
  • Indelicato DJ; Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, Florida, USA.
  • Morris CG; Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, Florida, USA.
  • Deraniyagala RL; Department of Radiation Oncology, Corewell Health/Beaumont Hospital, Royal Oak, Michigan, USA.
  • Fernandes RP; Department of Oral and Maxillofacial Surgery, University of Florida College of Medicine Jacksonville, Jacksonville, Florida, USA.
  • Bunnell AM; Department of Oral and Maxillofacial Surgery, University of Florida College of Medicine Jacksonville, Jacksonville, Florida, USA.
  • Nedrud SM; Department of Oral and Maxillofacial Surgery, University of Florida College of Medicine Jacksonville, Jacksonville, Florida, USA.
  • Mendenhall WM; Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, Florida, USA.
Int J Part Ther ; 11: 100008, 2024 Mar.
Article em En | MEDLINE | ID: mdl-38757074
ABSTRACT

Purpose:

Adenoid cystic carcinoma (ACC) is a rare malignancy accounting for 1% of all head and neck cancers. Treatment for ACC has its challenges and risks, yet few outcomes studies exist. We present long-term outcomes of patients with ACC of the head and neck treated with proton therapy (PT). Materials and

Methods:

Under an institutional review board-approved, single-institutional prospective outcomes registry, we reviewed the records of 56 patients with de novo, nonmetastatic ACC of the head and neck treated with PT with definitive (n = 9) or adjuvant PT (n = 47) from June 2007 to December 2021. The median dose to the primary site was 72.6 gray relative biological equivalent (range, 64-74.4) delivered as either once (n = 19) or twice (n = 37) daily treatments. Thirty patients received concurrent chemotherapy. Thirty-one patients received nodal radiation, 30 electively and 1 for nodal involvement.

Results:

With a median follow-up of 6.2 years (range, 0.9-14.7), the 5-year local-regional control (LRC), disease-free survival, cause-specific survival, and overall survival rates were 88%, 85%, 89%, and 89%, respectively. Intracranial extension (P = .003) and gross residual tumor (P = .0388) were factors associated with LRC rates. While the LRC rate for those with a gross total resection was 96%, those with subtotal resection or biopsy alone were 81% and 76%, respectively. The 5-year cumulative incidence of clinically significant grade ≥3 toxicity was 15%, and the crude incidence at the most recent follow-up was 23% (n = 13).

Conclusion:

This is the largest sample size with the longest median follow-up to date of patients with ACC treated with PT. PT can provide excellent disease control for ACC of the head and neck with acceptable toxicity. T4 disease, intracranial involvement, and gross residual disease at the time of PT following either biopsy or subtotal resection were significant prognostic features for worse outcomes.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article